MCO:NYSEMoody's Corporation Analysis
Data as of 2026-07-13 - not real-time
$493.31
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Moody's shares are trading at $493.31, comfortably above the 20‑day ($466.18), 50‑day ($455.57) and 200‑day ($471.09) moving averages, with a bullish MACD (+$3.31 histogram) and an RSI of 64, suggesting short‑term momentum remains intact. However, the stock commands a **price‑to‑earnings multiple of 35.4**, more than double the industry average of 17.7, and a price‑to‑book of 28.8, while the discounted cash‑flow model pins a fair value near $205, implying a substantial valuation gap.
Fundamentally, Moody's delivers strong profitability – 74% gross margin, 45.7% operating margin and a 31.7% net margin – and an eye‑popping ROE of 71%, driven by high leverage (debt‑to‑equity 235x) and solid cash generation (free cash flow $2.27 bn). The dividend is modest at 0.85% with a low 27.6% payout, indicating sustainability. Volatility is elevated (30‑day ≈30%) and trading volume has slipped sharply, raising liquidity concerns, while beta of ~0.6 points to limited market‑wide price swings. Recent analyst consensus remains positive (median target $532.5, ~8% upside) and the company’s inclusion in Russell value indices may broaden institutional demand.
Fundamentally, Moody's delivers strong profitability – 74% gross margin, 45.7% operating margin and a 31.7% net margin – and an eye‑popping ROE of 71%, driven by high leverage (debt‑to‑equity 235x) and solid cash generation (free cash flow $2.27 bn). The dividend is modest at 0.85% with a low 27.6% payout, indicating sustainability. Volatility is elevated (30‑day ≈30%) and trading volume has slipped sharply, raising liquidity concerns, while beta of ~0.6 points to limited market‑wide price swings. Recent analyst consensus remains positive (median target $532.5, ~8% upside) and the company’s inclusion in Russell value indices may broaden institutional demand.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price above key moving averages and bullish MACD
- RSI still in comfortable range (64)
- Analyst price targets indicating ~8% upside
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong profit margins and cash flow supporting dividend
- High leverage and valuation compression risk
- Potential institutional inflow from Russell value index inclusion
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- DCF fair value far below current price suggests downside risk
- Sustainable earnings but valuation remains stretched
- Regulatory environment and credit‑rating business stability
Key Metrics & Analysis
Financial Health
Revenue Growth8.10%
Profit Margin31.69%
P/E Ratio35.4
ROE71.36%
ROA14.82%
Debt/Equity235.54
P/B Ratio28.8
Op. Cash Flow$3.1B
Free Cash Flow$2.3B
Industry P/E17.7
Technical Analysis
TrendNeutral
RSI64.4
Support$437.51
Resistance$504.91
MA 20$466.18
MA 50$455.57
MA 200$471.09
MACDBullish
VolumeDecreasing
Fear & Greed Index92.16
Valuation
Fair Value$205.41
Target Price$539.90
Upside/Downside9.44%
GradeOvervalued
TypeBlend
Dividend Yield0.85%
Risk Assessment
Beta0.60
Volatility29.97%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.